{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tissue+tumor+biopsy&page=22", "query": { "intervention": "Tissue tumor biopsy", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 1096, "total_pages": 110, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tissue+tumor+biopsy&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tissue+tumor+biopsy&page=21&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T05:20:27.920Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01234532", "title": "Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor-negative Breast Cancer", "HER2-negative Breast Cancer", "Progesterone Receptor-negative Breast Cancer", "Stage I Breast Cancer", "Stage II Breast Cancer", "Stage IIIA Breast Cancer", "Triple-negative Breast Cancer" ], "interventions": [ { "name": "entinostat", "type": "DRUG" }, { "name": "anastrozole", "type": "DRUG" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 5, "start_date": "2010-10", "completion_date": "2017-05", "has_results": true, "last_update_posted_date": "2022-05-03", "last_synced_at": "2026-10-15T05:20:27.920Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01234532" }, { "nct_id": "NCT03201458", "title": "Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gallbladder Carcinoma", "Metastatic Cholangiocarcinoma", "Stage III Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8", "Unresectable Cholangiocarcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2018-02-08", "completion_date": "2024-02-19", "has_results": true, "last_update_posted_date": "2024-04-05", "last_synced_at": "2026-10-15T05:20:27.920Z", "location_count": 41, "location_summary": "Duarte, California • Sacramento, California • South Pasadena, California + 31 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Derby", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03201458" }, { "nct_id": "NCT07511504", "title": "Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Hepatocellular Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Unresectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "Angiogram", "type": "PROCEDURE" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Single Photon Emission Computed Tomography", "type": "PROCEDURE" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" }, { "name": "Yttrium-90 Microsphere Radioembolization", "type": "PROCEDURE" }, { "name": "Zanzalintinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2026-04-02", "completion_date": "2027-08-01", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-10-15T05:20:27.920Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT07511504" }, { "nct_id": "NCT05121038", "title": "CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colon Cancer", "Pancreas Cancer", "Digestive Cancer" ], "interventions": [ { "name": "CEND-1", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" }, { "name": "Folfirinox", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anup Kasi", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2021-10-20", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2024-12-17", "last_synced_at": "2026-10-15T05:20:27.920Z", "location_count": 3, "location_summary": "Fairway, Kansas • Kansas City, Kansas • North Kansas City, Missouri", "locations": [ { "city": "Fairway", "state": "Kansas" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "North Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05121038" }, { "nct_id": "NCT06305598", "title": "Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Carcinoma", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Leuprolide Acetate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Testosterone Cypionate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 3, "start_date": "2024-12-19", "completion_date": "2028-03-09", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-10-15T05:20:27.920Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06305598" }, { "nct_id": "NCT04274465", "title": "Application of Plasma Circulating HPV DNA Testing to Management of Cervical Intraepithelial Neoplasia", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cervix Lesion", "Cervical Cancer" ], "interventions": [ { "name": "digital PCR (dPCR) assay", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "FEMALE", "summary": "18 Years to 99 Years · Female only" }, "enrollment_count": 145, "start_date": "2020-02-26", "completion_date": "2024-07-15", "has_results": false, "last_update_posted_date": "2024-11-14", "last_synced_at": "2026-10-15T05:20:27.920Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04274465" }, { "nct_id": "NCT03941730", "title": "Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Triple-Negative Breast Carcinoma", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Triple-Negative Breast Carcinoma", "Recurrent Breast Carcinoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Therapeutic Estradiol", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 8, "start_date": "2019-08-28", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-10-15T05:20:27.920Z", "location_count": 9, "location_summary": "Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03941730" }, { "nct_id": "NCT05539365", "title": "Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Triple-Negative Breast Carcinoma", "Unresectable Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Alpha-type-1 Polarized Dendritic Cells", "type": "BIOLOGICAL" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2025-02-01", "completion_date": "2027-02-01", "has_results": false, "last_update_posted_date": "2025-01-29", "last_synced_at": "2026-10-15T05:20:27.920Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05539365" }, { "nct_id": "NCT01974765", "title": "Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Epithelial Ovarian", "Recurrent Epithelial Ovarian", "Fallopian Tube", "Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 59, "start_date": "2013-11-05", "completion_date": "2022-02-28", "has_results": true, "last_update_posted_date": "2023-04-28", "last_synced_at": "2026-10-15T05:20:27.920Z", "location_count": 6, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01974765" }, { "nct_id": "NCT00477100", "title": "Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Inflammatory Breast Carcinoma", "Invasive Breast Carcinoma", "Second Primary Malignant Neoplasm" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Interview", "type": "OTHER" }, { "name": "Medical Chart Review", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1200, "start_date": "2007-04-17", "completion_date": "2030-04-30", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-15T05:20:27.920Z", "location_count": 10, "location_summary": "Gilbert, Arizona • La Jolla, California • Greeley, Colorado + 6 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Greeley", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Saginaw", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00477100" } ] }